Fluvoxamine: First comprehensive insights into its molecular characteristics and inclusion complexation with β-cyclodextrin

Thammarat Aree

doi:10.1016/j.jpha.2024.101040

Volume 15 Issue 1

Feb. 2025

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2025 > 15(1): 101040

Thammarat Aree. Fluvoxamine: First comprehensive insights into its molecular characteristics and inclusion complexation with β-cyclodextrin[J]. Journal of Pharmaceutical Analysis, 2025, 15(1): 101040. doi: 10.1016/j.jpha.2024.101040

Citation:

Thammarat Aree. Fluvoxamine: First comprehensive insights into its molecular characteristics and inclusion complexation with β-cyclodextrin[J]. Journal of Pharmaceutical Analysis, 2025, 15(1): 101040. doi: 10.1016/j.jpha.2024.101040

Citation:

PDF( 4769 KB)

Fluvoxamine: First comprehensive insights into its molecular characteristics and inclusion complexation with β-cyclodextrin

doi: 10.1016/j.jpha.2024.101040

Thammarat Aree^,

Department of Chemistry, Faculty of Science, Chulalongkorn University, Bangkok, 10330, Thailand

Funds:

This work was supported by the Ratchadapisek Sompoch Endowment Fund, Chulalongkorn University, Thailand (Grant No.: RCU_67_023_010).

Received Date: Apr. 27, 2024
Accepted Date: Jul. 09, 2024
Rev Recd Date: Jun. 30, 2024
Publish Date: Jul. 14, 2024

Abstract

Abstract

Fluvoxamine (FXM) is a well-known selective serotonin reuptake inhibitor (SSRI) for treating depression and has recently been repurposed for efficacious treatment of coronavirus disease 2019. Although cyclodextrin (CD) encapsulation effectively improves the physicochemical properties of structurally diverse SSRIs, the molecular understanding of their associations is deficient. This comprehensive study used single-crystal X-ray diffraction integrated with density functional theory (DFT) calculation to provide deep insights into the conformationally flexible FXM and its inclusion complexation with β-CD. X-ray analysis revealed the first crystallographic evidence of the uncomplexed 3FXM-H⁺·3maleate^- ( 1 ). Three FXM-H⁺ ions are counter-balanced by three planar maleate^- ions to form a thin layer stabilized by infinite fused H-bond rings R₄⁴(12) and R₆⁴(16) and the interplay of π…π, CF…π and F…F interactions. For 2β-CD·2FXM-H⁺·maleate^2-·23·2H₂O ( 2 ), the tail-to-tail β-CD dimer encapsulates two FXM-H⁺ 4-(trifluoromethyl)phenyl moieties, which are charge-balanced by the rare non-planar maleate^2- and stabilized by N/OH…O H-bonds and F…F interactions. This is a host-guest recognition pattern uniquely observed for all β-CD complexes with halogen (X)-bearing SSRIs, indicating the essence of X…X interactions and the shielding of X-containing moieties in the wall of the β-CD dimer. DFT calculations unveiled that the monomeric and dimeric β-CD-FXM complexes and FXM isomers are energetically stable, which alleviates the numbness and bitterness of the orally administered drug as previously patented. Additionally, an insightful conformational analysis of FXM emphasizes the importance of drug structural adaptation in pharmacological functions.
- Conformational flexibility,
- β-Cyclodextrin,
- Fluvoxamine maleate,
- SSRIs,
- X-ray analysis,
- DFT calculation

FullText(HTML)

References(50)

References

[1]	World Health Organization (WHO), Depression and Other Common Mental Disorders: Global Health Estimates, (2017). http://apps.who.int/iris/bitstream/10665/254610/1/WHO-MSD-MER-2017.2-eng.pdf. (accessed January 24, 2024).
[2]	WHO, COVID-19 pandemic triggers 25% increase in prevalence of anxiety and depression worldwide, (2022). https://www.who.int/news/item/02-03-2022-covid-19-pandemic-triggers-25-increase-in-prevalence-of-anxiety-and-depression-worldwide. (accessed January 24, 2024).
[3]	R.H. Perlis, K. Ognyanova, M. Santillana, et al., Association of acute symptoms of COVID-19 and symptoms of depression in adults, JAMA Netw. Open 4 (2021), e213223.
[4]	H.E. Davis, L. McCorkell, J.M. Vogel, et al., Long COVID: Major findings, mechanisms and recommendations, Nat. Rev. Microbiol. 21 (2023) 408.
[5]	L. Brunton, B. Knollman, eds., Goodman and Gilman’s the Pharmacological Basis of Therapeutics, 14th ed., McGraw-Hill, 2023.
[6]	S.M. Stahl, Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 5th ed., Cambridge University Press, 2021.
[7]	M.J. Owens, D.L. Knight, C.B. Nemeroff, Second-generation SSRIs: Human monoamine transporter binding profile of escitalopram and R-fluoxetine, Biol. Psychiatry 50 (2001) 345-350.
[8]	F.J. MacKay, N.R. Dunn, L.V. Wilton, et al., A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies, Pharmacoepidemiol. Drug Saf. 6 (1997) 235-246.
[9]	I.M. Omori, N. Watanabe, A. Nakagawa, et al., Fluvoxamine versus other anti-depressive agents for depression, Cochrane Database Syst. Rev. (2010) CD006114.
[10]	G. Reis, E.A. Dos Santos Moreira-Silva, D.C.M. Silva, et al., Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: The TOGETHER randomised, platform clinical trial, Lancet Glob. Health 10 (2022) e42-e51.
[11]	H. Sidky, D.K. Sahner, A.T. Girvin, et al., Assessing the effect of selective serotonin reuptake inhibitors in the prevention of post-acute sequelae of COVID-19, medRxiv (2023) 2022.11.09.22282142.
[12]	Y. Hashimoto, T. Suzuki, K. Hashimoto, Mechanisms of action of fluvoxamine for COVID-19: A historical review, Mol. Psychiatry 27 (2022) 1898-1907.
[13]	J.W. Kwon, K.L. Armbrust, Photo-isomerization of fluvoxamine in aqueous solutions, J. Pharm. Biomed. Anal. 37 (2005) 643-648.
[14]	S. Dadkhah, S. Bagheri Novir, E. Balali, Computational investigation of structural and electronic properties of cis and trans structures of fluvoxamine as a nano-drug, Comput. Theor. Chem. 1105 (2017) 33-45.
[15]	K. Odai, T. Sugimoto, E. Ito, Quantum chemical calculation of intrinsic reaction coordinates from trans to cis structure of fluvoxamine, Comput. Theor. Chem. 1192 (2020), 113051.
[16]	G. Crini, L. Aleya, Cyclodextrin applications in pharmacy, biology, medicine, and environment, Environ. Sci. Pollut. Res. 29 (2022) 167-170.
[17]	S. Fourmentin, G. Crini, E. Lichtfouse, eds., Cyclodextrin Applications in Medicine, Food, Environment and Liquid Crystals, Springer International Publishing, Cham, 2018.
[18]	T. Aree, Advancing insights on β-cyclodextrin inclusion complexes with SSRIs through lens of X-ray diffraction and DFT calculation, Int. J. Pharm. 609 (2021), 121113.
[19]	T. Aree, Inclusion scenarios and conformational flexibility of the SSRI paroxetine as perceived from polymorphism of β-cyclodextrin-paroxetine complex, Pharmaceuticals (Basel) 15 (2022), 98.
[20]	T. Aree, Supramolecular assemblies of citalopram and escitalopram in β-cyclodextrin dimeric cavity: Crystallographic and theoretical insights, Carbohydr. Polym. 329 (2024), 121771.
[21]	S. Trefi, V. Gilard, S. Balayssac, et al., Quality assessment of fluoxetine and fluvoxamine pharmaceutical formulations purchased in different countries or via the Internet by ¹⁹F and 2D DOSY ¹H NMR, J. Pharm. Biomed. Anal. 46 (2008) 707-722.
[22]	L.S. Dastjerdi, M. Shamsipur, ¹⁹F-nuclear magnetic resonance spectroscopy as a tool to investigate host-guest complexation of some antidepressant drugs with natural and modified cyclodextrins, Trop. J. Pharm. Res. 15 (2017) 2675-2682.
[23]	Y. Yokoi, Inventor; Oral pharmaceutical compositions containing fluvoxamine maleate and cyclodextrins, Japan patent JP2011088858A, 6 May 2011.
[24]	Bruker, APEX2, SADABS and SHELXTL, (2014).
[25]	Bruker, SAINT and XPREP, (2008).
[26]	M.R. Caira, E. De Vries, L.R. Nassimbeni, et al., Inclusion of the antidepressant paroxetine in β-cyclodextrin, J. Incl. Phenom. Macrocycl. Chem. 46 (2003) 37-42.
[27]	P. Li, K. Guo, L. Fu, et al., Solubility-driven optimization of benzothiopyranone salts leading to a preclinical candidate with improved pharmacokinetic properties and activity against Mycobacterium tuberculosis, Eur. J. Med. Chem. 246 (2023), 114993.
[28]	A. Docker, T.G. Johnson, H. Kuhn, et al., Multistate redox-switchable ion transport using chalcogen-bonding anionophores, J. Am. Chem. Soc. 145 (2023) 2661-2668.
[29]	T. Aree, β-Cyclodextrin encapsulation of nortriptyline HCl and amitriptyline HCl: Molecular insights from single-crystal X-ray diffraction and DFT calculation, Int. J. Pharm. 575 (2020), 118899.
[30]	S.K. Panda, P.S.S. Gupta, M.K. Rana, Potential targets of severe acute respiratory syndrome coronavirus 2 of clinical drug fluvoxamine: Docking and molecular dynamics studies to elucidate viral action, Cell Biochem. Funct. 41 (2023) 98-111.
[31]	F.H. Allen, I.J. Bruno, Bond lengths in organic and metal-organic compounds revisited: X-H bond lengths from neutron diffraction data, Acta Crystallogr. B 66 (2010) 380-386.
[32]	M.J. Frisch, G.W. Trucks, H.B. Schlegel, et al., GAUSSIAN09, (2009).
[33]	S.F. Boys, F. Bernardi, The calculation of small molecular interactions by the differences of separate total energies. Some procedures with reduced errors, Mol. Phys. 19 (1970) 553-566.
[34]	H. Wang, A. Goehring, K.H. Wang, et al., Structural basis for action by diverse antidepressants on biogenic amine transporters, Nature 503 (2013) 141-145.
[35]	N. Mast, M. Linger, M. Clark, et al., In silico and intuitive predictions of CYP46A1 inhibition by marketed drugs with subsequent enzyme crystallization in complex with fluvoxamine, Mol. Pharmacol. 82 (2012) 824-834.
[36]	J.A. Coleman, E. Gouaux, Structural basis for recognition of diverse antidepressants by the human serotonin transporter, Nat. Struct. Mol. Biol. 25 (2018) 170-175.
[37]	S.S. Bharate, Carboxylic acid counterions in FDA-approved pharmaceutical salts, Pharm. Res. 38 (2021) 1307-1326.
[38]	C.R. Groom, I.J. Bruno, M.P. Lightfoot, et al., The Cambridge structural database, Acta Crystallogr. B Struct. Sci. Cryst. Eng. Mater. 72 (2016) 171-179.
[39]	T. Aree, Supramolecular complexes of β-cyclodextrin with clomipramine and doxepin: Effect of the ring substituent and component of drugs on their inclusion topologies and structural flexibilities, Pharmaceuticals (Basel) 13 (2020), 278.
[40]	Z. Zhou, J. Zhen, N.K. Karpowich, et al., Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures, Nat. Struct. Mol. Biol. 16 (2009) 652-657.
[41]	D.M.N. Abouhussein, M.A. El Nabarawi, S.H. Shalaby, et al., Sertraline-cyclodextrin complex orodispersible sublingual tablet: Optimization, stability, and pharmacokinetics, J. Pharm. Innov. 16 (2021) 53-66.
[42]	D.E. Koshland Jr, Protein and biological control, Sci. Am. 229 (1973) 52-64.
[43]	K. Lindner, W. Saenger, Crystal and molecular structure of cyclohepta-amylose dodecahydrate, Carbohydr. Res. 99 (1982) 103-115.
[44]	T. Aree, S. Jongrungruangchok, Crystallographic evidence for β-cyclodextrin inclusion complexation facilitating the improvement of antioxidant activity of tea (+)-catechin and (-)-epicatechin, Carbohydr. Polym. 140 (2016) 362-373.
[45]	D. Cremer, J.A. Pople, General definition of ring puckering coordinates, J. Am. Chem. Soc. 97 (1975) 1354-1358.
[46]	A.A. Bredikhin, Z.A. Bredikhina, D.V. Zakharychev, et al., Chiral drug timolol maleate as a continuous solid solution: Thermochemical and single crystal X-ray evidence, CrystEngComm 14 (2012) 648-655.
[47]	M. Parvez, Structure of an anhistaminic drug, racemic chlorpheniramine hydrogen maleate, Acta Crystallogr. C 46 (1990) 943-945.
[48]	A.H. Mazurek, L. Szeleszczuk, Current status of quantum chemical studies of cyclodextrin host-guest complexes, Molecules 27 (2022), 3874.
[49]	S. Tavoulari, L.R. Forrest, G. Rudnick, Fluoxetine (Prozac) binding to serotonin transporter is modulated by chloride and conformational changes, J. Neurosci. 29 (2009) 9635-9643.
[50]	W. Wang, W. Gong, S. Zhou, et al., β-cyclodextrin improve the tolerant of freshwater algal Spiny Scenedesmus to chiral drugs venlafaxine and its metabolite, J. Hazard. Mater. 399 (2020), 123076.